Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3200327 (SC)
LY3200327 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo (SC) | PLACEBO_COMPARATOR | Single subcutaneous (SC) dose of placebo |
| LY3200327 (SC) | EXPERIMENTAL | Single escalating subcutaneous (SC) dose of LY3200327 |
| LY3200327 (IV) | EXPERIMENTAL | Single intravenous (IV) dose of LY3200327 |
| Placebo (IV) | PLACEBO_COMPARATOR | Single intravenous (IV) dose of placebo |
| Name | Type | Description |
|---|---|---|
| Placebo (SC) | DRUG | Administered SC |
| LY3200327 (SC) | DRUG | Administered SC |
| LY3200327 (IV) | DRUG | Administered IV |
| Placebo (IV) | DRUG | Administered IV |
Inclusion Criteria: * At the time of initial screening, in general good health * First-generation healthy Japanese (age 20 to 65 years) will be included Exclusion Criteria: * Pregnancy or breastfeeding during the study * Chronic infection * Treatment with prohibited medications
LY3200327 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy participants. The specific therapeutic indication for LY3200327 has not been disclosed.
LY3200327 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker symbol LLY.
LY3200327 is in Phase 1 clinical development. It has not been approved by the FDA and remains investigational.
LY3200327 has been evaluated in one completed Phase 1 trial, NCT02595736, titled A Study of LY3200327 in Healthy Participants. The trial enrolled 52 healthy volunteers in the United States and was randomized, double-blind, and placebo-controlled.
Yes, LY3200327 (SC) is an alternative name for LY3200327. Both refer to the same investigational small molecule developed by Eli Lilly and Company.